

Natalizumab Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01405820	Biogen	Relapsing-Remitting Multiple Sclerosis	Aug-11	Phase 2
NCT01077466	Rigshospitalet, Denmark Copenhagen University Hospital, Hvidovre Biogen University of Copenhagen Signifikans ApS	Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis	Mar-10	Phase 2
NCT00030966	Biogen Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	Jan-02	Phase 3
NCT01071083	Biogen Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis	Mar-10	Phase 2
NCT02730455	Biogen	Acute Ischemic Stroke	18-Jul-16	Phase 2
NCT02159573	Biogen	Relapsing-Remitting Multiple Sclerosis	Jul-14	
NCT02133924	John Levine Biogen Icahn School of Medicine at Mount Sinai	Acute Graft Versus Host Disease	Aug-16	Phase 2
NCT01065727	Rennes University Hospital	Multiple Sclerosis	Feb-10	Not Applicable
NCT00297232	Biogen	Relapsing-Remitting Multiple Sclerosis	Mar-06	Phase 3
NCT00280956	Biogen Elan Pharmaceuticals	Crohn's Disease	Jul-02	Phase 4
NCT00942214	University Hospital, Toulouse	Multiple Sclerosis	Jun-09	Phase 4
NCT03689972	Biogen	Multiple Sclerosis, Relapsing-Remitting	26-Dec-18	Phase 3
NCT00675428	Biogen	Multiple Myeloma	Sep-08	Phase 1 Phase 2
NCT03093064	King's College London South London and Maudsley NHS Foundation Trust	Schizophrenia	April 1, 2017	Phase 1
NCT04580381	University Hospital, Caen Biogen	Multiple Sclerosis, Relapsing-Remitting	1-Sep-20	
NCT02137109	Biogen	Multiple Sclerosis	Mar-14	
NCT04964700	Multiple Sclerosis Center of Northeastern New York	Multiple Sclerosis	6-May-21	
NCT00559702	Biogen Elan Pharmaceuticals	Relapsing-Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis	Oct-07	Phase 1
NCT04832399	Biogen	Relapsing Remitting Multiple Sclerosis	12-Nov-13	
NCT03046251	State University of New York at Buffalo	Multiple Sclerosis	Aug-15	Phase 4
NCT04777539	Nantes University Hospital Rennes University Hospital	Multiple Sclerosis (MS)	17-Jun-21	
NCT00744679	Biogen Elan Pharmaceuticals	Multiple Sclerosis	Nov-08	Phase 4
NCT00801125	Biogen Elan Pharmaceuticals	Crohn's Disease	Dec-08	Phase 4
NCT00884481	Biogen	Relapsing-Remitting Multiple Sclerosis Fatigue	23-Mar-09	
NCT02342704	Biogen	Relapsing-Remitting Multiple Sclerosis	30-Nov-14	Phase 4
NCT00083759	Biogen Elan Pharmaceuticals	Rheumatoid Arthritis	May-04	Phase 2
NCT00493298	Biogen	Relapsing-Remitting Multiple Sclerosis	29-Jun-07	
NCT00818038	Biogen	Relapsing-Remitting Multiple Sclerosis	Mar-09	
NCT00032786	Biogen Elan Pharmaceuticals	Crohn's Disease	Mar-02	Phase 3
NCT00536120	Biogen	Multiple Sclerosis	Jan-08	Phase 4

NCT00707512	Biogen	Crohn's Disease	Jun-08	
NCT02775110	University at Buffalo	Multiple Sclerosis	Nov-12	Phase 4
NCT00276172	Biogen	Multiple Sclerosis	Dec-03	Phase 3
NCT01440101	Biogen	Multiple Sclerosis	Nov-10	Phase 2 Phase 3
NCT01884935	Biogen	Relapsing-Remitting Multiple Sclerosis	Jul-13	Phase 1
NCT01955707	Biogen	Acute Ischemic Stroke	Jan-14	Phase 2
NCT01144052	Claudio Gobbi Ospedale Civico, Lugano	Relapsing-remitting Multiple Sclerosis	Jun-10	Phase 4
NCT01485003	Biogen	Relapsing-Remitting Multiple Sclerosis	7-Feb-12	
NCT04225312	VU University Medical Center Stichting MS Research Innovatiefonds Zorgverzekeraard	Relapsing Remitting Multiple Sclerosis	3-Feb-20	Phase 4
NCT01943526	Biogen	Relapsing-Remitting Multiple Sclerosis	30-Nov-11	
NCT01416181	Biogen	Secondary Progressive Multiple Sclerosis	13-Sep-11	Phase 3
NCT02769689	University Hospital, Clermont-Ferrand	Multiple Sclerosis	April 2016	Phase 4
NCT01058005	Biogen Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis	Mar-10	Phase 3
NCT03811886	Case Comprehensive Cancer Center	Pulmonary Metastatic Osteosarcoma (pOS)	Sep-21	Phase 1 Phase 2
NCT00027300	Biogen Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	Nov-01	Phase 3
NCT01455220	University of South Florida	Multiple Sclerosis	Jan-11	Not Applicable
NCT01070836	Biogen	Relapsing Multiple Sclerosis	Mar-10	
NCT01591551	Cornerstone Health Care, PA Biogen	Multiple Sclerosis, Relapsing-Remitting	Mar-12	Phase 4
NCT00055536	Biogen Elan Pharmaceuticals	Crohn's Disease	April 2002	Phase 2
NCT03283371	Biogen	Epilepsy, Focal Seizures, Partial Seizures	20-Mar-18	Phase 2
NCT00871780	Biogen Elan Pharmaceuticals	Relapsing Remitting Multiple Sclerosis (RRMS)	Aug-09	Phase 4
NCT00424788	Biogen	Relapsing Forms of Multiple Sclerosis	Jan-07	Early Phase 1
NCT02176031	Dana-Farber Cancer Institute Biogen	Graft Versus Host Disease	Jan-15	Phase 2
NCT01070823	Biogen United BioSource, LLC Elan Pharmaceuticals	Multiple Sclerosis	Mar-10	
NCT02677077	Biogen	Relapsing-Remitting Multiple Sclerosis	31-Dec-15	
NCT00306592	Biogen Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	Mar-06	Phase 3
NCT02386566	Biogen	Multiple Sclerosis	20-Mar-15	
NCT02241785	Biogen	Relapsing Multiple Sclerosis	30-Sep-14	Phase 4
NCT00032799	Biogen Elan Pharmaceuticals	Crohn's Disease	Dec-01	Phase 3
NCT00055367	Biogen Elan Pharmaceuticals	Crohn's Disease	April 2002	Phase 2
NCT01416155	Biogen	Relapsing-Remitting Multiple Sclerosis Multiple Sclerosis	Oct-10	Phase 2
NCT00831649	Biogen Elan Pharmaceuticals	Rheumatoid Arthritis	Sep-04	Phase 2
NCT04048577	Berkovich, Regina MD, PhD Inc. Biogen Cedars-Sinai Medical Center	Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting	3-Jul-19	Phase 4
NCT02483845	Phoenix Neurological Associates, LTD	Inclusion Body Myositis (IBM)	May-13	Phase 1
NCT00078611	Biogen Elan Pharmaceuticals	Crohn's Disease	Mar-04	Phase 3
NCT02142192	Biogen	Relapsing Multiple Sclerosis	Dec-14	Phase 2

NCT03516526	VU University Medical Center Sanquin Plasma Products BV Erasmus Medical Center St. Antonius Hospital OLVG Rijnstate Hospital	Multiple Sclerosis	3-Nov-16	Phase 4
NCT02325440	University Hospital Muenster Novartis	Relapsing Remitting Multiple Sclerosis	Mar-14	Phase 4
NCT00097760	Biogen Elan Pharmaceuticals	Multiple Sclerosis, Relapsing-Remitting	Jun-03	Phase 2